Triptans and Lasmiditan Are Safe and Effective in Patients with Migraine Attacks Associated with Neurodevelopmental Disorders: A Single-Center Prospective Clinical Case Series

Background

Triptans and lasmiditan are considered specific acute medications for migraine attacks. Despite the efficacy of these treatments, continuation of these medications is limited because some patients experience adverse effects. A previous study reported a close association between migraine and neurodevelopmental disorders. The present study investigated triptans and lasmiditan in the treatment of consecutive patients with migraine attacks accompanied by neurodevelopmental disorders.